IRADIMED Management

Management criteria checks 4/4

IRADIMED's CEO is Roger Susi, appointed in Jan 2004, has a tenure of 20.33 years. total yearly compensation is $642.57K, comprised of 47.9% salary and 52.1% bonuses, including company stock and options. directly owns 36.23% of the company’s shares, worth €179.02M. The average tenure of the management team and the board of directors is 2.8 years and 7.9 years respectively.

Key information

Roger Susi

Chief executive officer

US$642.6k

Total compensation

CEO salary percentage	47.9%
CEO tenure	20.3yrs
CEO ownership	36.2%
Management average tenure	2.8yrs
Board average tenure	7.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Roger Susi's remuneration changed compared to IRADIMED's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	US$18m
Dec 31 2023	US$643k	US$308k	US$17m
Sep 30 2023	n/a	n/a	US$16m
Jun 30 2023	n/a	n/a	US$15m
Mar 31 2023	n/a	n/a	US$14m
Dec 31 2022	US$586k	US$290k	US$13m
Sep 30 2022	n/a	n/a	US$13m
Jun 30 2022	n/a	n/a	US$12m
Mar 31 2022	n/a	n/a	US$10m
Dec 31 2021	US$615k	US$308k	US$9m
Sep 30 2021	n/a	n/a	US$6m
Jun 30 2021	n/a	n/a	US$5m
Mar 31 2021	n/a	n/a	US$987k
Dec 31 2020	US$435k	US$290k	US$1m
Sep 30 2020	n/a	n/a	US$4m
Jun 30 2020	n/a	n/a	US$5m
Mar 31 2020	n/a	n/a	US$10m
Dec 31 2019	US$488k	US$288k	US$10m
Sep 30 2019	n/a	n/a	US$8m
Jun 30 2019	n/a	n/a	US$8m
Mar 31 2019	n/a	n/a	US$7m
Dec 31 2018	US$495k	US$279k	US$6m
Sep 30 2018	n/a	n/a	US$5m
Jun 30 2018	n/a	n/a	US$3m
Mar 31 2018	n/a	n/a	US$2m
Dec 31 2017	US$474k	US$268k	US$500k

Compensation vs Market: Roger's total compensation ($USD642.57K) is below average for companies of similar size in the German market ($USD1.08M).

Compensation vs Earnings: Roger's compensation has been consistent with company performance over the past year.

CEO

Roger Susi (70 yo)

20.3yrs

Tenure

US$642,566

Compensation

Mr. Roger E. Susi serves as President and Chief Executive Officer of IRadimed Corporation since May 28, 2020. He founded IRadimed Corporation in 2004 and has been its Chairman of the Board since June 10, 2...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Roger Susi	Founder	20.3yrs	US$642.57k	36.23% $ 179.0m
John Glenn	CFO & Corporate Secretary	1.9yrs	US$1.27m	0.054% $ 268.6k
Randy Waddell	Vice President of Worldwide Sales & Marketing	2.8yrs	US$597.28k	0.047% $ 233.3k
Chris Williamson	Executive Vice President of Continuous Improvement & Information Technology	1.9yrs	no data	no data
Matt Garner	Controller	4.3yrs	no data	no data
Steve Kachelmeyer	Vice President of Regulatory Affairs & Quality Assurance	no data	US$425.08k	0.042% $ 205.8k
Lynn Neuhardt	Vice President of Research & Development	no data	US$442.20k	0.050% $ 247.8k

2.8yrs

Average Tenure

Experienced Management: 46K's management team is considered experienced (2.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Roger Susi	Founder	7.9yrs	US$642.57k	36.23% $ 179.0m
James Hawkins	Director	4.9yrs	US$159.36k	0.31% $ 1.5m
Anthony Vuoto	Independent Director	8.2yrs	US$167.48k	0.13% $ 660.4k
Monty Allen	Independent Director	10.3yrs	US$169.98k	0.16% $ 780.4k
Hilda Scharen-Guivel	Independent Director	1.6yrs	US$153.11k	0.014% $ 68.9k

7.9yrs

Average Tenure

70yo

Average Age

Experienced Board: 46K's board of directors are considered experienced (7.9 years average tenure).

IRADIMED Management

Management criteria checks 4/4

Key information

Recent management updates

IRADIMED CORPORATION, Annual General Meeting, Jun 20, 2024

Independent Director recently sold €114k worth of stock

Independent Director recently sold €117k worth of stock

IRadimed Corporation Announces Board Changes

Independent Director recently sold €113k worth of stock

Insufficient new directors

Recent updates

IRADIMED CORPORATION Declares Regular Quarterly Cash Dividend, Payable on May 30, 2024

IRADIMED CORPORATION, Annual General Meeting, Jun 20, 2024

IRADIMED CORPORATION to Report Q1, 2024 Results on May 02, 2024

Full year 2023 earnings released: EPS: US$1.36 (vs US$1.02 in FY 2022)

Full year 2023 earnings released: EPS: US$1.36 (vs US$1.02 in FY 2022)

IRadimed Corporation Provides Revenue Guidance for the First Quarter and Full Year of 2024

IRadimed Corporation to Report Q4, 2023 Results on Feb 08, 2024

IRadimed Corporation Approves Initiation of Regular Quarterly Dividend, Payable on January 12, 2024

Independent Director recently sold €114k worth of stock

Third quarter 2023 earnings released: EPS: US$0.40 (vs US$0.27 in 3Q 2022)

Iradimed Corporation Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

IRadimed Corporation to Report Q3, 2023 Results on Nov 03, 2023

IRadimed Corporation Provides Earnings Guidance for the Third Quarter and for the Full Year of 2023

Second quarter 2023 earnings released: EPS: US$0.33 (vs US$0.26 in 2Q 2022)

IRadimed Corporation to Report Q2, 2023 Results on Aug 03, 2023

Independent Director recently sold €117k worth of stock

IRadimed Corporation Revises Earnings Guidance for the Year 2023

First quarter 2023 earnings released: EPS: US$0.27 (vs US$0.20 in 1Q 2022)

Investor sentiment deteriorates as stock falls 15%

Full year 2022 earnings released: EPS: US$1.02 (vs US$0.76 in FY 2021)

Iradimed Corporation Approves Special Cash Dividend, Payable on February 21, 2023

IRadimed Corporation to Report Q4, 2022 Results on Feb 02, 2023

Investor sentiment improves as stock rises 16%

IRadimed Corporation Provides Earnings Guidance for the First Quarter of 2023 and Full Year 2023

Third quarter 2022 earnings released: EPS: US$0.27 (vs US$0.21 in 3Q 2021)

Iradimed Corporation Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

IRadimed Corporation to Report Q3, 2022 Results on Nov 03, 2022

IRadimed Corporation Provides Revenue Guidance for the Third Quarter Ended September 30, 2022

IRadimed Corporation Announces Board Changes

Independent Director recently sold €113k worth of stock

Insufficient new directors

Second quarter 2022 earnings released: EPS: US$0.26 (vs US$0.12 in 2Q 2021)

Iradimed Corporation Revises Earnings Guidance for the Full Year 2022

IRadimed Corporation to Report Q2, 2022 Results on Jul 29, 2022

Insufficient new directors

IRadimed Corporation Names John F. Glenn as Chief Financial Officer, Effective on or before June 20, 2022

Investor sentiment deteriorated over the past week

First quarter 2022 earnings released: EPS: US$0.20 (vs US$0.11 in 1Q 2021)

Iradimed Corporation Revises Earnings Guidance for the Full Year 2022

IRadimed Corporation to Report Q1, 2022 Results on Apr 29, 2022

COO, CFO & Secretary recently sold €846k worth of stock

Investor sentiment improved over the past week

IRadimed Corporation Announces Special Share Cash Dividend, Payable on February 24, 2022

iRadimed Corporation Provides Earnings Guidance for the First Quarter and Full Year of 2022

Independent Director recently sold €785k worth of stock

Independent Director recently sold €119k worth of stock

Third quarter 2021 earnings released: EPS US$0.21 (vs US$0.088 in 3Q 2020)

Second quarter 2021 earnings released: EPS US$0.12 (vs US$0.17 loss in 2Q 2020)

First quarter 2021 earnings released: EPS US$0.11 (vs US$0.15 in 1Q 2020)

IRadimed Corporation Provides Financial Guidance for Fiscal Year 2021

Full year 2020 earnings released: EPS US$0.11 (vs US$0.85 in FY 2019)

Revenue beats expectations

New 90-day high: €21.40

IRadimed Corporation to Report Q4, 2020 Results on Feb 04, 2021

Third quarter 2020 earnings released: EPS US$0.088

Revenue beats expectations

New 90-day high: €19.40

Third quarter earnings released

Third-quarter earnings released: Revenue beats expectations

IRadimed Corporation to Report Q3, 2020 Results on Oct 30, 2020

IRadimed Corporation Withdraws Full-Year 2020 Financial Guidance and Not Providing Any Additional Financial Guidance

IRadimed Corporation to Report Q2, 2020 Results on Jul 30, 2020

IRadimed Corporation(NasdaqCM:IRMD) dropped from Russell 2000 Dynamic Index

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure